|
1
|
Ryan DP, Hong TS and Bardeesy N:
Pancreatic adenocarcinoma. N Engl J Med. 371:1039–1049. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zuckerman DS and Ryan DP: Adjuvant therapy
for pancreatic cancer: A review. Cancer. 112:243–249. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hsu CC, Herman JM, Corsini MM, Winter JM,
Callister MD, Haddock MG, Cameron JL, Pawlik TM, Schulick RD,
Wolfgang CL, et al: Adjuvant chemoradiation for pancreatic
adenocarcinoma: The Johns Hopkins Hospital-Mayo Clinic
collaborative study. Ann Surg Oncol. 17:981–990. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wolfgang CL, Herman JM, Laheru DA, Klein
AP, Erdek MA, Fishman EK and Hruban RH: Recent progress in
pancreatic cancer. CA Cancer J Clin. 63:318–348. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Adham M, Jaeck D, Le Borgne J,
Oussoultzouglou E, Chenard-Neu MP, Mosnier JF, Scoazec JY, Mornex F
and Partensky C: Long-term survival (5–20 years) after
pancreatectomy for pancreatic ductal adenocarcinoma: A series of 30
patients collected from 3 institutions. Pancreas. 37:352–357. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cleary SP, Gryfe R, Guindi M, Greig P,
Smith L, Mackenzie R, Strasberg S, Hanna S, Taylor B, Langer B and
Gallinger S: Prognostic factors in resected pancreatic
adenocarcinoma: Analysis of actual 5-year survivors. J Am Coll
Surg. 198:722–731. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shimada K, Sakamoto Y, Nara S, Esaki M,
Kosuge T and Hiraoka N: Analysis of 5-year survivors after a
macroscopic curative pancreatectomy for invasive ductal
adenocarcinoma. World J Surg. 34:1908–1915. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Huff V: Wilms' tumours: About tumour
suppressor genes, an oncogene and a chameleon gene. Nat Rev Cancer.
11:111–121. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Call KM, Glaser T, Ito CY, Buckler AJ,
Pelletier J, Haber DA, Rose EA, Kral A, Yeger H, Lewis WH, et al:
Isolation and characterization of a zinc finger polypeptide gene at
the human chromosome 11 Wilms' tumor locus. Cell. 60:509–520. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Osaka M, Koami K and Sugiyama T: WT1
contributes to leukemogenesis: Expression patterns in
7,12-dimethylbenz[a]anthracene (DMBA)-induced leukemia. Int J
Cancer. 72:696–699. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yang L, Han Y, Saiz Suarez F and Minden
MD: A tumor suppressor and oncogene: The WT1 story. Leukemia.
21:868–876. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sugiyama H: WT1 (Wilms' Tumor Gene 1):
Biology and cancer immunotherapy. Jap J Clin Oncol. 40:377–387.
2010. View Article : Google Scholar
|
|
14
|
Tatsumi N, Oji Y, Tsuji N, Tsuda A,
Higashio M, Aoyagi S, Fukuda I, Ito K, Nakamura J, Takashima S, et
al: Wilms' tumor gene WT1-shRNA as a potent apoptosis-inducing
agent for solid tumors. Int J Oncol. 32:701–711. 2008.PubMed/NCBI
|
|
15
|
Sciesielski LK, Kirschner KM, Scholz H and
Persson AB: Wilms' tumor protein Wt1 regulates the Interleukin-10
(IL-10) gene. FEBS Lett. 584:4665–4671. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Taube ET, Denkert C, Sehouli J, Kunze CA,
Dietel M, Braicu I, Letsch A and Darb-Esfahani S: Wilms tumor
protein 1 (WT1)-not only a diagnostic but also a prognostic marker
in high-grade serous ovarian carcinoma. Gynecol Oncol. 140:494–502.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Köbel M, Kalloger SE, Boyd N, McKinney S,
Mehl E, Palmer C, Leung S, Bowen NJ, Ionescu DN, Rajput A, et al:
Ovarian carcinoma subtypes are different diseases: Implications for
biomarker studies. PLoS Med. 5:e2322008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sera T, Hiasa Y, Mashiba T, Tokumoto Y,
Hirooka M, Konishi I, Matsuura B, Michitaka K, Udaka K and Onji M:
Wilms' tumour 1 gene expression is increased in hepatocellular
carcinoma and associated with poor prognosis. Eur J Cancer.
44:600–608. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Qi XW, Zhang F, Yang XH, Fan LJ, Zhang Y,
Liang Y, Ren L, Zhong L, Chen QQ, Zhang KY, et al: High Wilms'
tumor 1 mRNA expression correlates with basal-like and ERBB2
molecular subtypes and poor prognosis of breast cancer. Oncol Rep.
28:1231–1236. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lapillonne H, Renneville A, Auvrignon A,
Flamant C, Blaise A, Perot C, Lai JL, Ballerini P, Mazingue F,
Fasola S, et al: High WT1 expression after induction therapy
predicts high risk of relapse and death in pediatric acute myeloid
leukemia. J Clin Oncol. 24:1507–1515. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Qi XW, Zhang F, Wu H, Liu JL, Zong BG, Xu
C and Jiang J: Wilms' tumor 1 (WT1) expression and prognosis in
solid cancer patients: A systematic review and meta-analysis. Sci
Rep. 5:89242015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cheever MA, Allison JP, Ferris AS, Finn
OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL,
Weiner LM and Matrisian LM: The prioritization of cancer antigens:
A national cancer institute pilot project for the acceleration of
translational research. Clin Cancer Res. 15:5323–5337. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kaida M, Morita-Hoshi Y, Soeda A, Wakeda
T, Yamaki Y, Kojima Y, Ueno H, Kondo S, Morizane C, Ikeda M, et al:
Phase 1 trial of Wilms tumor 1 (WT1) peptide vaccine and
gemcitabine combination therapy in patients with advanced
pancreatic or biliary tract cancer. J Immunother. 34:92–99. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kimura Y, Tsukada J, Tomoda T, Takahashi
H, Imai K, Shimamura K, Sunamura M, Yonemitsu Y, Shimodaira S,
Koido S, et al: Clinical and immunologic evaluation of dendritic
cell-based immunotherapy in combination with gemcitabine and/or S-1
in patients with advanced pancreatic carcinoma. Pancreas.
41:195–205. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nishida S, Koido S, Takeda Y, Homma S,
Komita H, Takahara A, Morita S, Ito T, Morimoto S, Hara K, et al:
Wilms tumor gene (WT1) peptide-based cancer vaccine combined with
gemcitabine for patients with advanced pancreatic cancer. J
Immunother. 37:105–114. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kobayashi M, Shimodaira S, Nagai K,
Ogasawara M, Takahashi H, Abe H, Tanii M, Okamoto M, Tsujitani S,
Yusa S, et al: Prognostic factors related to add-on dendritic cell
vaccines on patients with inoperable pancreatic cancer receiving
chemotherapy: A multicenter analysis. Cancer Immunol Immunother.
63:797–806. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Koido S, Homma S, Okamoto M, Takakura K,
Mori M, Yoshizaki S, Tsukinaga S, Odahara S, Koyama S, Imazu H, et
al: Treatment with chemotherapy and dendritic cells pulsed with
multiple Wilms' tumor 1 (WT1)-specific MHC class I/II-restricted
epitopes for pancreatic cancer. Clin Cancer Res. 20:4228–4239.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mayanagi S, Kitago M, Sakurai T, Matsuda
T, Fujita T, Higuchi H, Taguchi J, Takeuchi H, Itano O, Aiura K, et
al: Phase I pilot study of Wilms tumor gene 1 peptide-pulsed
dendritic cell vaccination combined with gemcitabine in pancreatic
cancer. Cancer Sci. 106:397–406. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Oji Y, Nakamori S, Fujikawa M, Nakatsuka
S, Yokota A, Tatsumi N, Abeno S, Ikeba A, Takashima S, Tsujie M, et
al: Overexpression of the Wilms' tumor gene WT1 in pancreatic
ductal adenocarcinoma. Cancer Sci. 95:583–587. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Nakatsuka S, Oji Y, Horiuchi T, Kanda T,
Kitagawa M, Takeuchi T, Kawano K, Kuwae Y, Yamauchi A, Okumura M,
et al: Immunohistochemical detection of WT1 protein in a variety of
cancer cells. Mod Pathol. 19:804–814. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Naitoh K, Kamigaki T, Matsuda E, Ibe H,
Okada S, Oguma E, Kinoshita Y, Takimoto R, Makita K, Ogasawara S
and Goto S: Immunohistochemical analysis of WT1 antigen expression
in various solid cancer cells. Anticancer Res. 36:3715–3724.
2016.PubMed/NCBI
|
|
32
|
Mantovani A, Allavena P, Sica A and
Balkwill F: Cancer-related inflammation. Nature. 454:436–444. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gu L, Li H, Chen L, Ma X, Li X, Gao Y,
Zhang Y, Xie Y and Zhang X: Prognostic role of lymphocyte to
monocyte ratio for patients with cancer: Evidence from a systematic
review and meta-analysis. Oncotarget. 7:31926–31942. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sukharamwala P, Thoens J, Szuchmacher M,
Smith J and DeVito P: Advanced age is a risk factor for
post-operative complications and mortality after a
pancreaticoduodenectomy: A meta-analysis and systematic review. HPB
(Oxford). 14:649–657. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kinoshita S, Sho M, Yanagimoto H, Satoi S,
Akahori T, Nagai M, Nishiwada S, Yamamoto T, Hirooka S, Yamaki S,
et al: Potential role of surgical resection for pancreatic cancer
in the very elderly. Pancreatology. 15:240–246. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Amin MB, Greene FL, Edge SB, Compton CC,
Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR and
Winchester DP: The eighth edition AJCC cancer staging manual:
Continuing to build a bridge from a population-based to a more
‘personalized’ approach to cancer staging. CA Cancer J Clin.
67:93–99. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bing Z, Pasha TL, Acs G and Zhang PJ:
Cytoplasmic overexpression of WT-1 in gastrointestinal stromal
tumor and other soft tissue tumors. Appl immunohistochem Mol
Morphol. 16:316–321. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Martina JD, Simmons C and Jukic DM:
High-definition hematoxylin and eosin staining in a transition to
digital pathology. J Pathol Inform. 2:452011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Oji Y, Suzuki T, Nakano Y, Maruno M,
Nakatsuka S, Jomgeow T, Abeno S, Tatsumi N, Yokota A, Aoyagi S, et
al: Overexpression of the Wilms' tumor gene W T1 in primary
astrocytic tumors. Cancer Sci. 95:822–827. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Menssen HD, Renkl HJ, Rodeck U, Kari C,
Schwartz S and Thiel E: Detection by monoclonal antibodies of the
Wilms' tumor (WT1) nuclear protein in patients with acute leukemia.
Int J Cancer. 70:518–523. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Vajjhala PR, Macmillan E, Gonda T and
Little M: The Wilms' tumour suppressor protein, WT1, undergoes
CRM1-independent nucleocytoplasmic shuttling. FEBS Lett.
554:143–148. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Niksic M, Slight J, Sanford JR, Caceres JF
and Hastie ND: The Wilms' tumour protein (WT1) shuttles between
nucleus and cytoplasm and is present in functional polysomes. Hum
Mol Genet. 13:463–471. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ye Y, Raychaudhuri B, Gurney A, Campbell
CE and Williams BR: Regulation of WT1 by phosphorylation:
Inhibition of DNA binding, alteration of transcriptional activity
and cellular translocation. EMBO J. 15:5606–5615. 1996.PubMed/NCBI
|
|
44
|
Takahara A, Koido S, Ito M, Nagasaki E,
Sagawa Y, Iwamoto T, Komita H, Ochi T, Fujiwara H, Yasukawa M, et
al: Gemcitabine enhances Wilms' tumor gene WT1 expression and
sensitizes human pancreatic cancer cells with WT1-specific
T-cell-mediated antitumor immune response. Cancer Immunol
Immunother. 60:1289–1297. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Magro G, Salvatorelli L, Vecchio GM,
Musumeci G, Rita A and Parenti R: Cytoplasmic expression of Wilms
tumor transcription factor-1 (WT1): A useful immunomarker for
young-type fibromatoses and infantile fibrosarcoma. Acta Histochem.
116:1134–1140. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ito K, Oji Y, Tatsumi N, Shimizu S, Kanai
Y, Nakazawa T, Asada M, Jomgeow T, Aoyagi S, Nakano Y, et al:
Antiapoptotic function of 17AA(+)WT1 (Wilms' tumor gene) isoforms
on the intrinsic apoptosis pathway. Oncogene. 25:4217–4229. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Jomgeow T, Oji Y, Tsuji N, Ikeda Y, Ito K,
Tsuda A, Nakazawa T, Tatsumi N, Sakaguchi N, Takashima S, et al:
Wilms' tumor gene WT1 17AA(−)/KTS(−) isoform induces morphological
changes and promotes cell migration and invasion in vitro. Cancer
Sci. 97:259–270. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Oji Y, Tatsumi N, Kobayashi J, Fukuda M,
Ueda T, Nakano E, Saito C, Shibata S, Sumikawa M, Fukushima H, et
al: Wilms' tumor gene WT1 promotes homologous
recombination-mediated DNA damage repair. Mol Carcinog.
54:1758–1771. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Li BQ, Huang S, Shao QQ, Sun J, Zhou L,
You L, Zhang TP, Liao Q, Guo JC and Zhao YP: WT1-associated protein
is a novel prognostic factor in pancreatic ductal adenocarcinoma.
Oncol Lett. 13:2531–2538. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Jin DI, Lee SW, Han ME, Kim HJ, Seo SA,
Hur GY, Jung S, Kim BS and Oh SO: Expression and roles of Wilms'
tumor 1-associating protein in glioblastoma. Cancer Sci.
103:2102–2109. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Nishida S, Ishikawa T, Egawa S, Koido S,
Yanagimoto H, Ishii J, Kanno Y, Kokura S, Yasuda H, Oba MS, et al:
Combination gemcitabine and WT1 peptide vaccination improves
progression-free survival in advanced pancreatic ductal
adenocarcinoma: A phase II randomized study. Cancer Immunol Res.
2018 Jan 22;Doi: 10.1158/2326-6066.CIR-17-0386. View Article : Google Scholar
|
|
52
|
Koido S, Homma S, Okamoto M, Takakura K,
Gong J, Sugiyama H, Ohkusa T and Tajiri H: Chemoimmunotherapy
targeting Wilms' tumor 1 (WT1)-specific cytotoxic T lymphocyte and
helper T cell responses for patients with pancreatic cancer.
Oncoimmunology. 3:e9589502014. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Koido S, Okamoto M, Shimodaira S and
Sugiyama H: Wilms' tumor 1 (WT1)-targeted cancer vaccines to extend
survival for patients with pancreatic cancer. Immunotherapy.
8:1309–1320. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Wagner N, Michiels JF, Schedl A and Wagner
KD: The Wilms' tumour suppressor WT1 is involved in endothelial
cell proliferation and migration: Expression in tumour vessels in
vivo. Oncogene. 27:3662–3672. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Wagner KD, Cherfils-Vicini J, Hosen N,
Hohenstein P, Gilson E, Hastie ND, Michiels JF and Wagner N: The
Wilms' tumour suppressor Wt1 is a major regulator of tumour
angiogenesis and progression. Nat Commun. 5:58522014. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Folkman J: Tumor angiogenesis: Therapeutic
implications. New Engl J Med. 285:1182–1186. 1971. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Yang JJ, Hu ZG, Shi WX, Deng T, He SQ and
Yuan SG: Prognostic significance of neutrophil to lymphocyte ratio
in pancreatic cancer: A meta-analysis. World J Gastroenterol.
21:2807–2815. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Qi Q, Geng Y, Sun M, Wang P and Chen Z:
Clinical implications of systemic inflammatory response markers as
independent prognostic factors for advanced pancreatic cancer.
Pancreatology. 15:145–150. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Zhang P, Zou M, Wen X, Gu F, Li J, Liu G,
Dong J, Deng X, Gao J, Li X, et al: Development of serum parameters
panels for the early detection of pancreatic cancer. Int J Cancer.
134:2646–2655. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Chantrill LA, Nagrial AM, Watson C, Johns
AL, Martyn-Smith M, Simpson S, Mead S, Jones MD, Samra JS, Gill AJ,
et al: Precision medicine for advanced pancreas cancer: The
individualized molecular pancreatic cancer therapy (IMPaCT) trial.
Clinical Cancer Res. 21:2029–2037. 2015. View Article : Google Scholar
|
